Skip to main
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics Ltd is positioned favorably within the biotechnology sector due to its innovative product candidate, PrimeC, which has demonstrated a clean safety profile in recent clinical trials for both Alzheimer's and Amyotrophic Lateral Sclerosis (ALS). The company’s positive Phase 2 results enable it to advance into a pivotal Phase 3 trial, with the potential to secure partnerships and funding that could enhance its market presence and development capabilities. Furthermore, the strategic pathways for expanding PrimeC's application beyond ALS, supported by ongoing regulatory engagements, create a robust framework for future growth and value creation.

Bears say

NeuroSense Therapeutics has faced significant challenges with its clinical development, as delays in trial timelines and regulatory approvals could hinder its market entry and revenue generation potential. Financially, the company has demonstrated persistent cash burn, raising concerns regarding its liquidity and ability to fund ongoing research and development initiatives without significant capital infusions. Additionally, its reliance on a fixed-dose combination of established generic drugs may limit competitive differentiation and market appeal, further contributing to an unfavorable outlook for investors.

NRSN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 1 analysts, NRSN has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.